Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients.
Adolescent
Adult
Aged
Aged, 80 and over
Female
Humans
Immunohistochemistry
Male
Meningioma
/ metabolism
Middle Aged
Neuropilin-1
/ metabolism
Neuropilin-2
/ metabolism
Vascular Endothelial Growth Factor A
/ genetics
Vascular Endothelial Growth Factor Receptor-1
/ metabolism
Vascular Endothelial Growth Factor Receptor-2
/ metabolism
Vascular Endothelial Growth Factor Receptor-3
/ metabolism
Young Adult
Malignant meningioma
Meningioma
Neuropilin
VEGF
VEGF receptors
Journal
Journal of molecular histology
ISSN: 1567-2387
Titre abrégé: J Mol Histol
Pays: Netherlands
ID NLM: 101193653
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
24
06
2020
accepted:
04
12
2020
pubmed:
3
2
2021
medline:
15
12
2021
entrez:
2
2
2021
Statut:
ppublish
Résumé
Higher grade meningiomas tend to recur. We aimed to evaluate protein levels of vascular endothelial growth factor (VEGF)-A with the VEGF-receptors 1-3 and the co-receptors Neuropilin (NRP)-1 and -2 in WHO grade II and III meningiomas to elucidate the rationale for targeted treatments. We investigated 232 specimens of 147 patients suffering from cranial meningioma, including recurrent tumors. Immunohistochemistry for VEGF-A, VEGFR-1-3, and NRP-1/-2 was performed on tissue micro arrays. We applied a semiquantitative score (staining intensity x frequency). VEGF-A, VEGFR-1-3, and NRP-1 were heterogeneously expressed. NRP-2 was mainly absent. We demonstrated a significant increase of VEGF-A levels on tumor cells in WHO grade III meningiomas (p = 0.0098). We found a positive correlation between expression levels of VEGF-A and VEGFR-1 on tumor cells and vessels (p < 0.0001). In addition, there was a positive correlation of VEGF-A and VEGFR-3 expression on tumor vessels (p = 0.0034). VEGFR-2 expression was positively associated with progression-free survival (p = 0.0340). VEGF-A on tumor cells was negatively correlated with overall survival (p = 0.0084). The VEGF-A-driven system of tumor angiogenesis might still present a suitable target for adjuvant therapy in malignant meningioma disease. However, its role in malignant tumor progression may not be as crucial as expected. The value of comprehensive testing of the ligand and all receptors prior to administration of anti-angiogenic therapy needs to be evaluated in clinical trials.
Identifiants
pubmed: 33528717
doi: 10.1007/s10735-020-09940-2
pii: 10.1007/s10735-020-09940-2
pmc: PMC8012320
doi:
Substances chimiques
Neuropilin-2
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Neuropilin-1
144713-63-3
Vascular Endothelial Growth Factor Receptor-1
EC 2.7.10.1
Vascular Endothelial Growth Factor Receptor-2
EC 2.7.10.1
Vascular Endothelial Growth Factor Receptor-3
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
233-243Références
Baumgarten P, Brokinkel B, Zinke J et al (2013) Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas. Histol Histopathol 28:1157–66
pubmed: 23475388
Baumgarten P, Harter PN, Tönjes M et al (2014) Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity. Neuropathol Appl Neurobiol 40:205–216. https://doi.org/10.1111/nan.12088
doi: 10.1111/nan.12088
pubmed: 24117486
Baumgarten P, Blank A-E, Franz K, et al (2015) Differential expression of vascular endothelial growth factor (VEGF)-A, its receptors VEGFR-1, -2 and -3 and co-receptors Neuropilin (NRP)-1 and -2 does not predict Bevacizumab response in human astrocytomas. Neuro Oncol in press:1–11. https://doi.org/ https://doi.org/10.1093/neuonc/nov288
Baumgarten P, Blank A-E, Franz K et al (2016) Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1,-2, and-3 and co-receptors neuropilin-1 and-2 does not predict bevacizumab response in human astrocytomas. Neuro Oncol. https://doi.org/10.1093/neuonc/nov288
doi: 10.1093/neuonc/nov288
pubmed: 26627848
pmcid: 5782506
Baumgarten P, Gessler F, Schittenhelm J et al (2016) Brain invasion in otherwise benign meningiomas does not predict tumor recurrence. Acta Neuropathol. https://doi.org/10.1007/s00401-016-1598-1
doi: 10.1007/s00401-016-1598-1
pubmed: 27464983
Gerber HP, Condorelli F, Park J, Ferrara N (1997) Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 272:23659–67
doi: 10.1074/jbc.272.38.23659
Kaley TJ, Wen P, Schiff D et al (2015) Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol 17:116–21. https://doi.org/10.1093/neuonc/nou148
doi: 10.1093/neuonc/nou148
pubmed: 25100872
Kawasaki T, Kitsukawa T, Bekku Y et al (1999) A requirement for neuropilin-1 in embryonic vessel formation. Development 126:4895–902
pubmed: 10518505
Kirkegaard T, Edwards J, Tovey S et al (2006) Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48:787–794. https://doi.org/10.1111/j.1365-2559.2006.02412.x
doi: 10.1111/j.1365-2559.2006.02412.x
pubmed: 16722926
Lou E, Sumrall AL, Turner S et al (2012) Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol 109:63–70. https://doi.org/10.1007/s11060-012-0861-0
doi: 10.1007/s11060-012-0861-0
pubmed: 22535433
pmcid: 3404217
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
doi: 10.1007/s00401-016-1545-1
pubmed: 27157931
Nakada S, Sasagawa Y, Tachibana O et al (2019) The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival. Brain Tumor Pathol 36:7–13. https://doi.org/10.1007/s10014-018-0332-1
doi: 10.1007/s10014-018-0332-1
pubmed: 30519894
Nassehi D, Sørensen LP, Dyrbye H et al (2013) Peritumoral brain edema in angiomatous supratentorial meningiomas: An investigation of the vascular endothelial growth factor A pathway. APMIS 121:1025–1036. https://doi.org/10.1111/apm.12052
doi: 10.1111/apm.12052
pubmed: 23398358
Nassiri F, Mamatjan Y, Suppiah S et al (2019) Neuro-Oncology in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncol 21:901–910. https://doi.org/10.1093/neuonc/noz061
doi: 10.1093/neuonc/noz061
pubmed: 31158293
pmcid: 6620635
Nayak L, Iwamoto FM, Rudnick JD et al (2012) Atypical and anaplastic meningiomas treated with bevacizumab. J Neuro Oncol. https://doi.org/10.1007/s11060-012-0886-4
doi: 10.1007/s11060-012-0886-4
Pan Q, Chathery Y, Wu Y et al (2007) Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem 282:24049–56. https://doi.org/10.1074/jbc.M703554200
doi: 10.1074/jbc.M703554200
pubmed: 17575273
Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 356:133–135
doi: 10.1038/356133a0
Preusser M, Hassler M, Birner P et al (2012) Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. Clin Neuropathol 31:352–360. https://doi.org/10.5414/NP300488
doi: 10.5414/NP300488
pubmed: 22541785
Reszec J, Hermanowicz A, Rutkowski R et al (2015) Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema. Biomed Res Int 2015:646853. https://doi.org/10.1155/2015/646853
doi: 10.1155/2015/646853
pubmed: 25821815
pmcid: 4363610
Ryan HE, Lo J, Johnson RS (1998) HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17:3005–3015. https://doi.org/10.1093/emboj/17.11.3005
doi: 10.1093/emboj/17.11.3005
pubmed: 9606183
pmcid: 1170640
Sahm F, Schrimpf D, Stichel D et al (2017) DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. https://doi.org/10.1016/S1470-2045(17)30155-9
doi: 10.1016/S1470-2045(17)30155-9
pubmed: 28314689
Scholz A, Harter PN, Cremer S, et al (2015) Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol Med. https://doi.org/ https://doi.org/10.15252/emmm.201505505
Shibuya M, Claesson-Welsh L (2006) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312:549–560. https://doi.org/10.1016/j.yexcr.2005.11.012
doi: 10.1016/j.yexcr.2005.11.012
pubmed: 16336962
Shih KC, Chowdhary S, Rosenblatt P et al (2016) A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neurooncol 129:281–288. https://doi.org/10.1007/s11060-016-2172-3
doi: 10.1007/s11060-016-2172-3
pubmed: 27311730
Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 356:133–135
doi: 10.1038/356133a0
Soker S, Takashima S, Miao HQ et al (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735–45
doi: 10.1016/S0092-8674(00)81402-6
Tirand L, Frochot C, Vanderesse R et al (2006) A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. J Control Release 111:153–164. https://doi.org/10.1016/j.jconrel.2005.11.017
doi: 10.1016/j.jconrel.2005.11.017
pubmed: 16423422
Ulyatt C, Walker J, Ponnambalam S (2011) Hypoxia differentially regulates VEGFR1 and VEGFR2 levels and alters intracellular signaling and cell migration in endothelial cells. Biochem Biophys Res Commun 404:774–9. https://doi.org/10.1016/j.bbrc.2010.12.057
doi: 10.1016/j.bbrc.2010.12.057
pubmed: 21168388
van Netten JP, Thornton IG, Carlyle SJ et al (1987) Multiple microsample analysis of intratumor estrogen receptor distribution in breast cancers by a combined biochemical/immunohistochemical method. Eur J Cancer Clin Oncol 23:1337–1342. https://doi.org/10.1016/0277-5379(87)90117-9
doi: 10.1016/0277-5379(87)90117-9
pubmed: 2824208